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Abstract
Background Patients with moderate-to-severe psoriasis require long-term treatment, yet few trials compare outcomes
beyond a short-term induction period. Quantitative comparisons of long-term outcomes in patients with psoriasis are
limited. To our knowledge, no network meta-analysis (NMA) of such data has been performed.
Objective To compare novel systemic therapies, both biologic and non-biologic, approved for moderate-to-severe
psoriasis by conducting a systematic review (SR) and NMA of Psoriasis Area and Severity Index (PASI) outcomes mea-
sured at or around 1 year.
Methods An SR was conducted to identify studies reporting PASI 75, PASI 90 and PASI 100 responses. Feasibility of
an NMA on maintenance phase endpoints was assessed and sources of heterogeneity considered. Data appropriate for
analysis were modelled using a Bayesian multinomial likelihood model with probit link. Wherever possible, data corre-
sponding to an intention-to-treat approach with non-responder imputation were used.
Results Twenty-four studies reporting outcomes at 40–64 weeks were identified, but heterogeneity in study design
allowed synthesis of only 17. Four 52-week randomized controlled trials (RCTs) comprised the primary analysis, which
found brodalumab was significantly more efficacious than secukinumab, ustekinumab and etanercept. Secukinumab
was also more efficacious than ustekinumab and both outperformed etanercept. In a secondary analysis, evidence from
13 additional studies and 4 further therapies (adalimumab, apremilast, infliximab and ixekizumab) was included by com-
paring long-term outcomes from active interventions to placebo outcomes extrapolated from induction. Results were
consistent with the primary analysis: brodalumab was most effective, followed by ixekizumab and secukinumab, then
ustekinumab, infliximab and adalimumab. Etanercept and apremilast had the lowest expected long-term efficacy.
Results were similar when studies with low prior exposure to biological therapies were excluded.
Conclusion Results suggest that brodalumab is associated with a higher likelihood of sustained PASI response,
including complete clearance, at week 52 than comparators. Further long-term active-comparator RCT data are required
to better assess relative efficacy across therapies.
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Introduction
Psoriasis is a common inflammatory skin condition, estimated
to affect 2–3% of the worldwide population.1 Moderate-to-
severe chronic plaque psoriasis symptoms have a significant neg-
ative impact on patient quality of life2 and are associated with a
considerable economic burden.3 Approximately 90% of cases
require long-term therapy4; therefore, therapies with favourable
efficacy and safety as demonstrated in longer-term trials stand to
make a meaningful difference to the lives of patients.5
Treatments such as the anti-tumour necrosis factor (TNF)
therapies, adalimumab, etanercept and infliximab, and the
interleukin (IL)-12/23 inhibitor, ustekinumab, transformed the
treatment of psoriasis when they were approved. More
recently, three therapies focusing on the IL-17 pathway have
been approved: secukinumab and ixekizumab, both IL-17A
inhibitors, and brodalumab, a human monoclonal antibody
which targets the IL-17 receptor A (IL-17RA) on keratinocytes
and immune cells. These biological therapies, along with the
phosphodiesterase 4 (PD4) inhibitor apremilast, have proven
to be effective options for many patients, though they are typ-
ically available only to patients with moderate-to-severe disease
who have failed or are ineligible for conventional systemic
therapy.
Despite their importance, comparisons of long-term out-
comes in patients with psoriasis are limited due to complicated
trial designs and inconsistencies in analysis and data handling
methods used.6 Many long-term trials have multiple phases, are
not clear or consistent in how they deal with imputations of
missing observations or even in which population outcomes are
being analysed. For these reasons, most systematic literature
reviews (SLRs) and meta-analyses in psoriasis have focused on
induction phase outcomes. One 2015 review and meta-analysis
compared 24-week outcomes of standard systemic and biological
therapies,7 though the authors also noted limitations of the
long-term data available. Since then, several 52-week random-
ized controlled trials (RCTs) have been published demonstrating
the longer-term efficacy of some licensed therapies. To our
knowledge, no formal synthesis of these outcomes has been
attempted.
With so many therapies licensed for moderate-to-severe pso-
riasis and only a few compared directly in a head-to-head fash-
ion, traditional pairwise meta-analysis alone is insufficient to
guide practical clinical decision making. Network meta-analysis
(NMA) offers a set of methods to visualize and interpret a broad
evidence base and to determine the comparative efficacy of mul-
tiple interventions.8 The technique borrows strength from indi-
rect evidence to enable the simultaneous evaluation of relative
effects that have not been investigated directly in RCTs9 and has
been used extensively to evaluate short-term effects of psoriasis
treatments.10–24
The objective of this study was to compare novel systemic
therapies, both biologic and non-biologic, approved for the
treatment of moderate-to-severe psoriasis by conducting a SLR
and NMA of Psoriasis Area and Severity Index (PASI) outcomes
measured at or around 1 year.
Materials and methods
Systematic literature review
An SLR was performed to identify RCT evidence that assessed
the efficacy of biologic therapies and apremilast in adult patients
with moderate-to-severe chronic plaque psoriasis. PRISMA
(Preferred Reporting Items for Systematic reviews and Meta-
Analyses and network meta-analyses) reporting guidelines were
followed throughout.25,26
MEDLINE, Embase and Cochrane Library databases were
searched for articles published in English from 2000 to 31
August 2016 (Table S1). Search strings combined terms related
to psoriasis, to specific therapies and to RCTs. Screening of
potentially relevant publications was performed double-blind,
with a third reviewer resolving any differences as to eligibility.
Supplementary searching included a bibliography review, con-
gress abstract searching and hand searching. Bibliographies of
included studies were cross-referenced with the search results to
identify additional studies. Abstracts of relevant disease-specific
and health economics and outcomes research congresses from
2013 to 31 August 2016 were searched. Finally, a hand search
was performed in February 2017 to identify additional full-text
publications reporting on trials that had been included as
abstracts in the original SLR.
Only RCTs comparing an intervention of interest – adali-
mumab, apremilast, brodalumab, etanercept, infliximab, ixek-
izumab, secukinumab and ustekinumab – with any comparator,
including placebo and unlicensed doses of biological and non-
biological systemic therapies, were included in the systematic
review. The NMA included only doses of biological therapies
and apremilast licensed by the European Medicines Agency
(EMA). The main outcome of interest was the proportion of
patients achieving 75%, 90% and 100% improvements in PASI
score at between 40- and 64-week follow-up (PASI 75, PASI 90
and PASI 100).
For each study meeting the inclusion criteria, study design
details, patient demographics, therapy details, efficacy endpoints
and statistical analyses were extracted, with particular attention
paid to patient follow-up and the handling of missing data. The
methodological quality of included studies was assessed using
the Cochrane Risk of Bias Tool.27 Potential risk of bias was
determined by assessing heterogeneity of treatment and outcome
characteristics as well as study and patient characteristics.
Analysis
To determine the feasibility and appropriateness of analysis,
included studies were compared to assess heterogeneity in terms
of treatment and outcome characteristics as well as study and
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patient characteristics. The planning and execution of all analy-
ses adhered to internationally recommended methods.28,29 Rele-
vant study results were combined by means of a hierarchical
Bayesian NMA of PASI responses using an ordered probit model
to estimate probabilities of achieving different levels of response
(e.g. PASI 75, PASI 90 and PASI 100). This is the preferred
model when synthesizing ordered categorical data as it makes
efficient use of all available trial data, even where different trials
use different thresholds or report different numbers of thresh-
olds, by assuming that the treatment effect is the same regardless
of response level.29,30 Prior exposure to biological therapies var-
ies across trials of psoriasis and is thought to be an potential
effect modifier; therefore, a sensitivity analysis was run excluding
studies which do not report or in which <5% of patients report
prior experience with biologics.
Results were generated using both fixed- and random-effects
models, and compared for goodness of fit to the data, calculated
as the overall mean residual deviance. The model with the lowest
deviance information criterion (DIC) was considered to have
the ‘best’ fit to the data.29 Inconsistency between direct and indi-
rect estimates of effect was assessed for any loops in the evidence
network using the two-stage Bucher method.30,31
All analyses were performed using WinBUGS version 1.4 statis-
tical software with non-informative priors. An initial burn-in of
at least 20 000 simulations was used, and convergence was con-
firmed through visual inspection the Brook–Gelman–Rubin diag-
nostic and history plots. This was followed by 50 000 simulations
on three chains to estimate the sampled parameters. Results are
calculated as risk ratios (RRs) for each treatment compared to
one another. Point estimates of the median value are presented,
along with 95% credible intervals (95% CrI) reflecting the range
of true effects with 95% probability. A numerical summary of
each treatment’s rank distribution, called the surface under the
cumulative ranking (SUCRA) curve, is also presented.
Results
Literature search results
Electronic searches identified 3441 publications, to which sup-
plementary searching added a total of 31 additional references.
After deduplication, 2997 titles and abstracts were screened, and
full-text versions of 225 publications were assessed. In total, 98
publications, covering 67 RCTs, were included (Fig. 1).
Evidence network
Of the 98 publications identified in the SLR, 62 publications
describing 54 RCTs reported PASI outcomes for a licensed dose
of biologic therapy or apremilast at the end of a 10- to 16-week
induction period. Twenty-four of these RCTs also reported on
PASI outcomes measured at 40–64 weeks of follow-up, but pla-
cebo- and active-controlled data were limited. Most control
arms did not continue beyond the short-term induction period,
yet controlled data are necessary to calculate comparative effect
estimates.
Five studies were long-term RCTs for which maintenance
phase data were available for at least two trial arms. Fourteen
studies were RCTs with a short-term induction phase followed
by an observational maintenance phase in which patients origi-
nally randomized to placebo crossed over to active therapy. Five
studies were short-term RCTs with a crossover maintenance
phase followed by a rerandomized withdrawal-controlled phase
among treatment responders. From this heterogeneous data set
of longer-term outcomes, several analyses were planned and
implemented (Fig. 2).
References identified through 
database searching, n = 3441
Embase: 2373  
Medline: 590
Cochrane Library: 478
Abstracts screened after duplicates 
removed
n = 2997
Full text papers assessed for 
eligibility
n = 225
Publications included in SLR
n = 98
Duplicate records: 444
Abstracts that did not meet 
inclusion criteria: 2772
• Duplicate: 637
• Patient population: 730
• Study design: 1081
• Outcomes: 324
Supplementary searching: 31
• Hand searching: 19
• Congress abstracts: 12
Papers that did not meet 
inclusion criteria of SLR: 158
• Patient population: 18
• Intervention: 16
• Outcomes: 24
• Duplicate: 32
• Study design: 68
Papers that did not meet 
inclusion criteria of NMA: 76
Supplementary data sources 
for included studies: 4
• Hand searches: 4
Publications included in NMA
n = 26 (24 RCTs)
Figure 1 PRISMA flow diagram of SLR.
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Analysis 1: NMA of 52-week active therapy RCTs
The primary analysis utilized data from four of the active-con-
trolled 52-week RCTs32–34 evaluating brodalumab, ustekinumab
(weight-based dosing: 45 mg if <100 kg; 90 mg if >100 kg),
secukinumab and etanercept (50 mg BIW). The fifth study,
PIECE,35 was excluded due to its small sample size (n = 19) and
the risk for Type II error.
Analysis 2: NMA of 52-week RCTs using induction phase
placebo control
Building on the primary network, a secondary analysis was
undertaken using evidence from 13 of the 14 crossover main-
tenance phase trials. The PHOENIX 2 trial was excluded due
to outcomes being insufficiently reported for use in the analy-
sis.36,37 By design, these maintenance phases are like single-
arm studies, and thus data are non-comparative. To use these
data in the NMA, maintenance phase responses from licensed
active therapy arms were compared to induction phase out-
comes from placebo arms. This assumes that if patients ran-
domized to placebo at the start of the trial had continued
receiving placebo, there would have been no change in their
likelihood or level of response. Making this assumption
allowed for the inclusion of data for adalimumab, apremilast,
infliximab and ixekizumab, as well as additional data for
etanercept, secukinumab and ustekinumab (45 and 90 mg).
Only data for patients starting on the licensed induction dose
followed by the licensed maintenance dose were used. Main-
tenance phase data relating to patients who crossed over from
unlicensed induction doses were excluded.
Data from the five studies with a withdrawal-controlled phase
were not included in the secondary analysis.38–41 The responder-
enrichment design of these studies, that is the restriction of
rerandomization only to patients who reached a predefined level
of response, may bias results in favour of the active intervention.
A description of the 22 RCTs included in the primary and sec-
ondary analyses is provided in Table 1, and an evidence network
for both analyses is provided in Fig. 3. A total of 2244 patients
were included in the four 52-week RCTs. A total of 6113 patients
were included in the 17 trials forming the augmented network
for PASI response. In the sensitivity analysis around prior bio-
logic exposure, six studies42–47 were excluded from the aug-
mented network. Study-level outcomes are reported in Table S2.
Direct and indirect treatment effects were compared in the loops
of evidence observed in the augmented network (Analysis 2),
but no significant inconsistency was identified.
Risk of bias
The risk of bias among the included studies was somewhat
heterogeneous, but most were rated as being low risk of bias
(Figure S1). Of the 17 included RCTs, four (24%) reported an
adequate randomization method and 14 (82%) supplied suffi-
cient information to assess whether allocation concealment was
properly ensured. In four studies, the blinding of participants
and personnel was insufficient as the long-term extension was
open label.42,47,48 In all studies, the risk of attrition bias was low,
as incomplete outcome data were sufficiently addressed. The risk
of reporting bias was low in most of the studies. The risk of bias
for each study is presented in Figure S2.
Efficacy
Analysis 1: NMA of 52-week active therapy RCTs The relative
treatment effects for comparisons between brodalumab, ustek-
inumab (weight-based dosing), secukinumab and etanercept
(50 mg twice weekly) are presented in Table 2. Results indicate
that brodalumab is associated with significantly higher propor-
tions of PASI 75, PASI 90 and PASI 100 responders compared to
secukinumab, ustekinumab and etanercept. Secukinumab was
24 induction phase RCTs with long-term follow-up 
5 induction phase RCTs with responder-
enriched re-randomised withdrawal 
controlled trial
Included
0 studies
Excluded 
5 studies (study 
design likely to bias 
results)
5
52-week RCTs
Included 
4 studies
Excluded 
1 study 
(small sample size)
NMA of 52-week
active therapy RCTs
14 induction phase RCTs with placebo 
cross-over and observational maintenance 
phase
Included 
13 studies
Excluded 
1 study 
(poorly reported 
outcomes)
NMA of 52-week
RCTs using induction phase 
placebo control 
Figure 2 Study selection for network meta-analysis (NMA).
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also found to be more efficacious than ustekinumab, and both
were found to outperform etanercept.
Analysis 2: NMA of 52-week RCTs using induction phase placebo
control Results of the analysis in which maintenance phase
outcomes for active therapies were compared to induction phase
outcomes for placebo showed all treatments to be significantly
more efficacious than placebo. In terms of PASI responses, the
most effective therapies in the network were brodalumab fol-
lowed by ixekizumab and secukinumab, whereas apremilast
Secukinumab300 mg
Brodalumab 210mg Etanercept  50mg BIW
Ustekinumab
CLEAR
AMAGINE-2 
AMAGINE-3
Ustekinumab 45mg
Ustekinumab 90mg
PHOENIX 1
Igarashi 2012
Placebo
Apremilast 30 mg
Ixekizumab Q2W  Q4W
Adalimumab 40mg
Infliximab  5 mg/kg
PHOENIX 1
Igarashi 2012
FIXTURE
Tyring 2008
Torii 2010
EXPRESS
EXPRESS II
JUNCTURE
FEATURE
ERASURE
X-PLORE
Gordon 2006
LIBERATE
PHOENIX 1
Igarashi 2012
UNCOVER-3
Primary analysis of active-controlled trials
Secondary placebo-assisted analysis
Figure 3 Network diagram of Psoriasis Area and Severity Index (PASI) responses – primary and secondary analyses.
Table 2 NMA of 52-week active therapy RCTs (Analysis 1): results on PASI responses
Intervention vs. Comparator Median risk ratio (95% credible interval)
PASI 75 PASI 90 PASI 100
BRO SEC 1.10 (1.01–1.41) 1.17 (1.03–1.61) 1.32 (1.06–2.02)
UST 1.27 (1.05–1.94) 1.46 (1.1–2.41) 1.90 (1.26–3.46)
ETN 1.65 (1.11–3.65) 2.11 (1.23–5.34) 3.31 (1.58–10.00)
SEC UST 1.15 (1.03–1.48) 1.23 (1.05–1.67) 1.4 (1.12–2.07)
ETN 1.49 (1.10–2.66) 1.79 (1.19–3.49) 2.48 (1.44–5.39)
UST ETN 1.28 (1.05–2.00) 1.43 (1.09–2.42) 1.73 (1.18–3.29)
Results from fixed-effect multinomial likelihood model with probit link and presented as risk ratios, with 95% credible intervals in parentheses below.
BRO, brodalumab 210 mg; ETN, etanercept 50 mg twice weekly; NMA, network meta-analysis; PASI, Psoriasis Area and Severity Index; RCTs, randomized
controlled trials; SEC, secukinumab 300 mg; UST, ustekinumab (45 mg if <100 kg; 90 mg if >100 kg).
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Table 3 NMA of 52-week RCTs using induction phase placebo control (Analysis 2): results on PASI responses
Intervention vs. Comparator Median risk ratio (95% Credible Interval)
PASI 75 PASI 90 PASI 100
BRO SEC 1.1 (1.01, 1.41) 1.18 (1.03, 1.63) 1.32 (1.06, 2.02)
IXE 1.06 (0.96, 1.46) 1.11 (0.93, 1.73) 1.21 (0.89, 2.23)
UST 1.27 (1.05, 1.94) 1.49 (1.11, 2.48) 1.91 (1.27, 3.48)
UST 45 mg 1.2 (1.02, 2.04) 1.37 (1.04, 2.72) 1.68 (1.09, 4.06)
UST 90 mg 1.13 (1, 1.75) 1.24 (1, 2.21) 1.43 (1, 3.1)
APR 3.22 (1.36, 16.4) 5.47 (1.75, 36.35) 11.61 (2.72, 103.4)
ADA 1.31 (1.02, 2.89) 1.57 (1.04, 4.32) 2.07 (1.08, 7.5)
ETN 1.63 (1.11, 3.54) 2.15 (1.25, 5.43) 3.26 (1.57, 9.64)
INF 1.25 (1.02, 2.26) 1.45 (1.06, 3.11) 1.84 (1.12, 4.84)
PBO 19.86 (3.5, 231) 53.14 (6.7, 775.6) 201.7 (18.01, 3683)
SEC IXE 0.98 (0.82, 1.16) 0.96 (0.74, 1.24) 0.93 (0.64, 1.37)
UST 1.15 (1.03, 1.48) 1.25 (1.06, 1.71) 1.42 (1.13, 2.09)
UST 45 mg 1.09 (0.96, 1.57) 1.15 (0.93, 1.87) 1.26 (0.89, 2.39)
UST 90 mg 1.03 (0.89, 1.35) 1.05 (0.84, 1.54) 1.09 (0.76, 1.84)
APR 2.91 (1.33, 12.4) 4.58 (1.67, 24.39) 8.66 (2.42, 58.94)
ADA 1.19 (0.95, 2.26) 1.32 (0.91, 3.05) 1.56 (0.86, 4.58)
ETN 1.48 (1.1, 2.59) 1.82 (1.2, 3.49) 2.45 (1.44, 5.18)
INF 1.13 (0.97, 1.73) 1.23 (0.96, 2.13) 1.39 (0.93, 2.84)
PBO 18.03 (3.44, 170) 44.82 (6.46, 504.3) 151.3 (16.51, 2003)
IXE UST 1.17 (1.01, 1.68) 1.29 (1.01, 2.08) 1.5 (1.02, 2.8)
UST 45 mg 1.12 (0.96, 1.66) 1.2 (0.94, 2.04) 1.35 (0.91, 2.72)
UST 90 mg 1.05 (0.9, 1.43) 1.09 (0.84, 1.68) 1.16 (0.77, 2.11)
APR 2.98 (1.34, 13) 4.78 (1.7, 26.17) 9.29 (2.52, 65.72)
ADA 1.22 (0.96, 2.38) 1.38 (0.94, 3.28) 1.67 (0.9, 5.1)
ETN 1.5 (1.1, 2.85) 1.87 (1.21, 4.05) 2.59 (1.44, 6.51)
INF 1.16 (0.99, 1.84) 1.28 (0.98, 2.33) 1.48 (0.96, 3.25)
PBO 18.51 (3.46, 177.2) 46.92 (6.56, 534.5) 162.7 (17.11, 2210)
UST UST 45 mg 0.97 (0.74, 1.25) 0.94 (0.65, 1.37) 0.91 (0.54, 1.56)
UST 90 mg 0.91 (0.67, 1.11) 0.86 (0.57, 1.16) 0.78 (0.45, 1.25)
APR 2.5 (1.27, 9.27) 3.62 (1.5, 16.57) 6 (1.94, 35.29)
ADA 1.04 (0.75, 1.77) 1.07 (0.66, 2.19) 1.11 (0.54, 2.91)
ETN 1.27 (1.05, 1.93) 1.43 (1.09, 2.37) 1.69 (1.17, 3.12)
INF 1 (0.77, 1.36) 0.99 (0.69, 1.54) 0.99 (0.58, 1.82)
PBO 15.54 (3.32, 122.8) 35.42 (5.96, 326.1) 104.7 (13.98, 1133)
UST 45 mg UST 90 mg 0.95 (0.79, 1.02) 0.91 (0.72, 1.03) 0.87 (0.63, 1.04)
APR 2.61 (1.3, 9.76) 3.86 (1.56, 17.79) 6.63 (2.1, 39.03)
ADA 1.08 (0.79, 1.86) 1.13 (0.7, 2.35) 1.22 (0.59, 3.23)
ETN 1.31 (1.05, 2.16) 1.51 (1.09, 2.8) 1.85 (1.16, 3.97)
INF 1.03 (0.8, 1.44) 1.06 (0.72, 1.67) 1.09 (0.62, 2.05)
PBO 16.25 (3.38, 127) 37.97 (6.18, 344) 116.4 (15.09, 1220)
UST 90 mg APR 2.78 (1.32, 11.16) 4.28 (1.63, 21.28) 7.78 (2.3, 49.65)
ADA 1.14 (0.88, 2.08) 1.24 (0.81, 2.74) 1.41 (0.73, 3.98)
ETN 1.4 (1.08, 2.46) 1.67 (1.15, 3.33) 2.17 (1.3, 5.02)
INF 1.09 (0.89, 1.61) 1.15 (0.84, 1.94) 1.26 (0.77, 2.53)
PBO 17.33 (3.43, 149.5) 42.07 (6.37, 426.3) 136.7 (16.04, 1619)
APR ADA 0.43 (0.12, 0.83) 0.31 (0.07, 0.73) 0.19 (0.03, 0.62)
ETN 0.52 (0.18, 0.88) 0.4 (0.12, 0.82) 0.29 (0.07, 0.73)
INF 0.4 (0.11, 0.79) 0.28 (0.06, 0.66) 0.17 (0.03, 0.51)
PBO 5.83 (2.29, 22.01) 9.09 (3.11, 39.46) 16.05 (4.62, 82.94)
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showed the poorest efficacy of achieving any level of PASI
response (Table 3 and Figure S3).
Figure 4 presents the cumulative ranking curves for each
treatment along with an estimate of the SUCRA line. A SUCRA
would be 100% when a treatment is certain to be the best and
0% when it is certain to be the worst. Brodalumab was ranked
the most efficacious therapy in 79% of Bayesian iterations, giv-
ing it the highest SUCRA value of 97%. Ixekizumab and
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Figure 4 Cumulative ranking probability plots and surface under the cumulative ranking (SUCRA) for each treatment included in network
meta-analysis (NMA) of 52-week randomized controlled trials (RCTs) using induction phase placebo control (Analysis 2). On the horizontal
axis is the possible rank of each treatment according to the magnitude of its treatment effect across all measures of Psoriasis Area and
Severity Index (PASI) response (from the best rank [1] to worst [11]). On the vertical axis is the cumulative probability for each treatment to
be the best option, among the best two options, among the best three options and so on. If a treatment always ranks first, then the
SUCRA = 100%; if a treatment always ranks last, then the SUCRA = 0%. WBD, weight-based dose.
Table 3 Continued
Intervention vs. Comparator Median risk ratio (95% Credible Interval)
PASI 75 PASI 90 PASI 100
ADA ETN 1.18 (0.82, 2.04) 1.3 (0.76, 2.63) 1.48 (0.69, 3.76)
INF 0.96 (0.57, 1.39) 0.93 (0.46, 1.6) 0.9 (0.34, 1.98)
PBO 14.51 (3.29, 107.6) 31.98 (5.81, 283.5) 90.38 (13.29, 976.8)
ETN INF 0.8 (0.49, 0.99) 0.71 (0.39, 0.98) 0.6 (0.28, 0.96)
PBO 12.14 (3.13, 68.57) 24.49 (5.3, 154.4) 61.07 (11.2, 428.2)
INF PBO 15.57 (3.35, 117.1) 35.53 (6.05, 309.4) 105.3 (14.43, 1053)
Results from fixed-effect multinomial likelihood model with probit link.
ADA, adalimumab 40 mg Q2W; APR, apremilast 30 mg BID; BID, twice daily; BIW, twice weekly; BRO, brodalumab 210 mg; ETN, etanercept 50 mg BIW;
INF, infliximab 5 mg/kg; IXE, ixekizumab 80 mg Q2W?Q4W; NMA, network meta-analysis; PASI, Psoriasis Area and Severity Index; PBO, placebo; Q2W,
every 2 weeks; Q4W, every 4 weeks; RCTs, randomized controlled trials; SEC, secukinumab 300 mg; UST, ustekinumab (45 mg if <100 kg; 90 mg if
>100 kg).
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secukinumab had the next highest SUCRA values, at 83% and
77%, respectively. Of active therapies, etanercept and apremilast
had the lowest SUCRA values, at just 22% and 10%, respectively.
Results from the sensitivity analysis including only studies
with at least 5% of patients reporting prior biologic exposure
were consistent with the analysis including all studies regardless
of prior biologic exposure (Table S3). With the exception of
apremilast, for which there were no data in this sensitivity analy-
sis, the relative rank and statistical significance of treatments
effects between treatments were unchanged.
Discussion
We performed a comprehensive systematic review and NMA
summarizing the long-term RCT evidence available for the effi-
cacy of systemic biologic and non-biologic drugs in the treat-
ment of patients with moderate-to-severe psoriasis. This is the
first NMA to synthesize maintenance phase outcomes reported
at or around 1 year of follow-up.
The synthesis of four RCTs reporting PASI outcomes at week
52 for brodalumab, ustekinumab, secukinumab and etanercept
showed brodalumab to be associated with the highest likelihood
of response. Based on these results, patients treated with bro-
dalumab are 30% more likely to experience a complete clearance
of psoriasis (PASI 100) at 1 year than patients treated with
secukinumab, almost twice as likely as those treated with a
weight-based dose of ustekinumab and more than three times as
likely as patients treated with a 50 mg twice weekly dose of etan-
ercept.
We supplemented this ‘purer’ network with the inclusion of
placebo-controlled RCTs reporting maintenance phase out-
comes for other licensed therapies, including adalimumab,
apremilast, infliximab and ixekizumab. The newest generation
biologic therapies – brodalumab, ixekizumab and secukinumab
– were the best performing treatments, followed by ustek-
inumab, infliximab and adalimumab. Etanercept and apremilast
had the lowest expected long-term efficacy.
These findings are generally consistent with published
NMAs on the induction phase efficacy of biologics for psoria-
sis and with a published meta-analysis of 24-week outcomes.
Nast et al.7 ranked drugs based on PASI 75 responses at
24 weeks, with the best results reported for infliximab, secuk-
inumab and ustekinumab followed by adalimumab, etanercept
and apremilast.
Patient registries, such as BADBIR in the United Kingdom
and DERMBIO in Denmark, are another valuable source of
long-term data on the efficacy of biologic therapies for psoriasis.
Several studies reporting analyses of drug survival from registry
or other observational data sets have been published, and they
showed ustekinumab to have similar49 or longer drug survival
compared to anti-TNF agents.50–59 It will be some time before
published data are available for the newest biologics – bro-
dalumab, ixekizumab and secukinumab – yet the RCT evidence
and this analysis suggest that they will outperform older biolog-
ics in the long-term.
Limitations
A number of challenges arise when attempting to quantitatively
summarize the results of long-term studies in psoriasis. They
vary in study design, in their method of analysis and in their
handling of missing data. Wherever possible, we used data from
the intention-to-treat analysis population and the more conser-
vative non-responder imputation method. We included out-
comes for patients receiving the licensed regimen of the
intervention throughout each study, thus excluding patients
who had crossed over following induction.
In the majority of long-term RCTs, the placebo groups were
discontinued after induction. As comparative data are funda-
mental to meta-analysis (both pairwise and network), we
imputed these missing long-term outcomes for placebo by carry-
ing forward responses measured at the end of induction (10–
16 weeks). We are aware that this approach is associated with
uncertainties; however, the stability of placebo responses
recorded between the end of induction up to week 24 in four
RCTs45,60–62 lends some support to our assumption. In their
meta-analysis of 24-week outcomes, Nast et al.7 dealt with this
problem by calculating a mean placebo response from three
studies that reported placebo data up to week 24 and used it as a
model for trials without a long-term placebo control, a method
of adjustment that breaks randomization. More long-term direct
evidence is required to increase the quantity and validity of pos-
sible comparisons, thus active-controlled RCTs make the most
sense ethically and methodologically.
The number of therapies coming to market for the treatment
of moderate-to-severe psoriasis is evolving rapidly, and already
licensed therapies are still being evaluated in active-comparator
trials. Since the search was performed for this systematic review,
three treatments have received marketing authorization for pso-
riasis in either the United States, Europe or both: guselkumab,
certolizumab pegol and tildrakizumab. Due to their very nature,
systematic reviews are challenged by the rate of publications in
this disease area, and further updates will inevitably be required
as and when long-term RCT data mature for these newer
therapies.
Conclusions
This NMA of long-term RCT evidence demonstrates that high
levels of sustained efficacy can be expected from IL-17A inhibi-
tor secukinumab, and IL-17RA receptor blocker brodalumab,
with brodalumab achieving the highest rates of PASI response
up to and including PASI 100. Our secondary analysis indirectly
compared the IL-17 blocking agents with older biologics and
apremilast, and although there was more uncertainty, it sup-
ported the conclusion that IL-17A inhibitors and the IL-17RA
receptor blocker are the most efficacious medicines in the
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currently available treatment arsenal to treat moderate-to-severe
psoriasis. Long-term active-comparator trials are needed to
validate these conclusions.
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